Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an ...
Physician's Weekly2d
7 Risk Factors Identified for Cognitive Impairment in COPD
Given the rising prevalence of cognitive impairment in COPD, researchers have called for increased efforts to identify risk ...
MPR2d
Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.
Health on MSN5d
What's the Difference Between Asthma and Chronic Obstructive Pulmonary Disease (COPD)?
Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...
Sanofi: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.